A comparative trial of sodium meglumine ioxaglate (Hexabrix) and iopamidol (Niopam) for cerebral angiography.
We have carried out a randomized blind trial comparing iopamidol (Niopam) and sodium meglumine ioxaglate (Hexabrix) in cerebral angiography in 50 patients. There was no significant difference in the degree of pain or movement produced by the contrast media. The degree of heat felt was slightly greater with iopamidol than with ioxaglate. Both were very well tolerated by patients, producing only a mild or moderate sensation of heat, and in only a few instances slight pain during the injections. No difference in radiographic quality was observed. We conclude that both media are a significant advance over the conventional ionic media and the choice between them will be determined by factors of neurotoxicity, ease of use and cost.
D002339:Carotid Arteries; D002533:Cerebral Angiography; D002986:Clinical Trials as Topic; D003287:Contrast Media / Q000009:adverse effects; D006801:Humans; D007463:Iodobenzoates; D007479:Iopamidol; D007483:Iothalamic Acid / Q000009:adverse effects / Q000031:analogs & derivatives*; D007485:Ioxaglic Acid; D011897:Random Allocation; D014283:Triiodobenzoic Acids / Q000009:adverse effects; D014711:Vertebral Artery
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007483:Iothalamic Acid; D007479:Iopamidol; D007485:Ioxaglic Acid